Related Experiment Video
Updated: Jun 4, 2026
Isolation of Human Primary Valve Cells for In vitro Disease Modeling
Published on: April 16, 2021
Disease-Associated Remodeling of m6A RNA Methylation in Human Interstitial Cells From Fibro-Calcific Aortic Valves
Vincenza Valerio1, Omar Molla2, Ilaria Massaiu1
1Applied Biotechnology in Cardiovascular Inflammation, Centro Cardiologico Monzino IRCCS, Milan, Italy.
Insights
RNA modifications change in calcific aortic valve disease (CAVD). These epitranscriptomic patterns in valvular interstitial cells may drive disease progression, offering new therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Calcific aortic valve disease (CAVD) is a prevalent condition in aging populations, leading to significant aortic stenosis.
- Current treatments for severe CAVD primarily involve valve replacement, as effective drugs to slow disease progression are lacking.
- Emerging research indicates that RNA modifications may play a role in the cellular changes associated with CAVD.
Purpose of the Study:
- To compare epitranscriptomic profiles of human valvular interstitial cells from healthy and diseased aortic valves.
- To identify specific RNA modification patterns associated with the progression of calcific aortic valve disease.
- To uncover potential molecular targets for non-surgical therapeutic interventions in CAVD.
Main Methods:
- Isolation and comparative analysis of human valvular interstitial cells from non-calcified and fibro-calcific stenotic aortic valves.
- Direct RNA sequencing to profile and compare RNA modification landscapes between control and diseased cells.
- Network-based analysis to prioritize genes involved in disease-associated signaling pathways.
Main Results:
- Distinct epitranscriptomic patterns were identified, clearly differentiating healthy from diseased valvular interstitial cells.
- An overall increase in RNA modification sites was observed in diseased cells, with specific site-gains and losses noted.
- Prioritization analysis highlighted genes related to extracellular matrix remodeling, inflammation, and stress response.
Conclusions:
- Disease-associated RNA modification remodeling is linked to key cellular programs in calcific aortic valve disease.
- These findings suggest that epitranscriptomic alterations contribute to the pathogenesis of CAVD.
- The identified RNA modification patterns and associated genes represent promising targets for future research and potential non-surgical therapies.
Abstract:
Calcific aortic valve disease is common in older adults and a major cause of aortic stenosis. Despite its clinical impact, there are still no effective drugs that slow disease progression, and treatment largely relies on surgical or transcatheter valve replacement once stenosis becomes severe and symptomatic. Beyond established roles for inflammation and tissue remodeling, recent evidence suggests that chemical modifications of RNA may influence how valve cells shift toward fibro-calcific states. In this study, we compared human valvular interstitial cells isolated from non-calcified valves and from fibro-calcific stenotic valves, profiling RNA modifications using direct RNA sequencing. The resulting epitranscriptomic patterns clearly separated control from diseased cells and revealed an overall increase in detected modification sites in disease, alongside site-specific gains and losses across selected transcripts. Network-based prioritization highlighted genes linked to extracellular matrix remodeling and inflammatory signaling, pointing to stress-responsive regulators as notable candidates. Overall, these findings support the idea that disease-associated RNA modification remodeling accompanies, and may help shape, key cellular programs in calcific valve disease, providing a focused set of targets for future functional validation and potential non-surgical therapeutic exploration.
More Related Videos
Related Concept Videos
01:22Mitral Stenosis I: Introduction
01:27Mitral Valve Prolapse I: Introduction
01:23Rheumatic Heart Disease I: Introduction